The litigation, led by the law firm Faruqi & Faruqi, LLP, centers on allegations that GeneDx and its executives misled shareholders regarding the strategic value of Fabric Genomics and the long-term durability of reimbursement rates. According to the complaint, these omissions resulted in artificially inflated stock prices prior to the company’s Q1 2026 financial disclosure.
On May 4, 2026, GeneDx reported that its exome and genome revenue lines fell below expectations. The company simultaneously lowered its 2026 revenue guidance to a range of $475–$490 million, down from previous projections of $540–$555 million. Additionally, the company revealed a $31.3 million goodwill impairment charge related to Fabric Genomics—a unit acquired just one year earlier for $36.5 million. Following these disclosures, the company's share price dropped more than 49%, or $33.42 per share. Investors seeking to discuss their legal options or the lead plaintiff process may contact partner Josh Wilson at 877-247-4292.
Comments (0)
No comments yet. Be the first!